Skip to main content

Search articles in Biotechnology

Found 143 articles

  • Boehringer Ingelheim and OSE Immunotherapeutics ex

    Boehringer Ingelheim and OSE Immunotherapeutics expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

    • 22 May 2024
    • Editor

    Two new projects to develop first-in-class treatments will be added to the ongoing anti-SIRPα immuno-oncology programs. The first involves broadening the therapeutic evaluation of an already partnered asset to reach more patients and the other a new asset acquisition.

  • HaemaLogiX welcomes former Australian Federal Mini

    HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director

    • 21 May 2024
    • Editor

    HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to the HaemaLogiX Board as a Non-Executive Director.

  • Sanofi and Novavax announce co-exclusive licensing

    Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

    • 10 May 2024
    • Editor

    As part of Sanofi’s commitment to developing a diverse portfolio of best-in-class vaccines, the company has entered into a co-exclusive licensing agreement with Novavax, a biotechnology company headquartered in Maryland, US.

  • Vertex and TreeFrog Therapeutics Announce Licensin

    Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes

    • 24 Apr 2024
    • Editor

    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex’s cell therapies for type 1 diabetes (T1D).

  • Vertex Enters Into Agreement to Acquire Alpine Imm

    Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

    • 11 Apr 2024
    • Editor

    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.

  • Immutep Announces First Clinical Data from 90mg Do

    Immutep Announces First Clinical Data from 90mg Dosing of Efti

    • 6 Mar 2024
    • Editor

    Immutep (Formerly known as Prima Biomed) Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha (efti) in combination with weekly paclitaxel in patients from the safety lead-in (N=6) of the AIPAC-003 Phase II/III trial.

  • Zymeworks Announces Appointment Of Dr. Alessandra

    Zymeworks Announces Appointment Of Dr. Alessandra Cesano To Its Board Of Directors

    • 9 Feb 2024
    • Editor

    Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Alessandra Cesano to its board of directors effective February 8, 2024.

  • Top 10 Pharma and Biotech Companies in Germany 202

    Top 10 Pharma and Biotech Companies in Germany 2024

    • 25 Jan 2024
    • Lucy Walters

    The country is home to more than 600 pharmaceutical companies, with the pharma industry employing around 140,000 people. In this article, we highlight the top 10 biotech and pharma companies in Germany as of 2023, based on their market capitalisation.

  • The Future of Biotech Talent Acquisition: Trends a

    The Future of Biotech Talent Acquisition: Trends and Predictions for 2024

    • 23 Jan 2024
    • Lucy Walters

    The global biotechnology market was estimated at $1.37 trillion in 2022, with an expected compound annual growth rate of 13.96% between 2023 and 2030. As the industry continues to evolve at an unprecedented rate, talent acquisition professionals within the life science industry face unique challenges when it comes to attracting and retaining the top talent needed to propel this growth.

  • Biotech companies to increase R&D spend but highli

    Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON

    • 9 Jan 2024
    • Editor

    ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper. This provides an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilise investment funding.

  • GPN VACCINES REPORTS POSITIVE SAFETY AND IMMUNOGEN

    GPN VACCINES REPORTS POSITIVE SAFETY AND IMMUNOGENICITY DATA FROM ITS PHASE 1 TRIAL OF GAMMA-PN

    • 4 Jan 2024
    • Editor

    GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase 1 trial of Gamma-PN, a non-adjuvanted whole cell-pneumococcal vaccine being investigated in adults aged 50 to 69 years.

  • Moderna Announces Changes to Commercial Organizati

    Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025

    • 13 Dec 2023
    • Editor

    The Company is focused on driving continued sales of its COVID-19 vaccine and launching its RSV vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward. The Company has decided to increase executive focus on driving sales of Spikevax and the expected launch of its RSV vaccine next year.

  • UK biotech fundraising picks up with best quarterl

    UK biotech fundraising picks up with best quarterly total since 2021

    • 9 Nov 2023
    • Editor

    The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.

  • Bicycle Therapeutics Reports Recent Business Progr

    Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day

    • 3 Nov 2023
    • Editor

    Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2023, and provided recent corporate updates.

  • Memo Therapeutics AG Raises CHF 25 Million Series

    Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients

    • 3 Nov 2023
    • Editor

    Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 million Series C financing led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group, Fresenius Medical Care Ventures and Red Alpine joined in the round.

  • BioMarin Announces Retirement of Jean-Jacques Bien

    BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer

    • 2 Nov 2023
    • Editor

    BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, announced today that Alexander Hardy has been named president and chief executive officer, succeeding Jean-Jacques Bienaimé, who will retire as chairman and CEO effective December 1, 2023. Mr. Hardy, currently the CEO of Genentech, will also serve as a director on BioMarin's board of directors.

  • AstraZeneca announces collaboration and investment

    AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions

    • 1 Nov 2023
    • Editor

    AstraZeneca today announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

  • CEPI and Moderna Harness mRNA Technology to Advanc

    CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission

    • 30 Oct 2023
    • Editor

    The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. (NASDAQ:MRNA) have entered into a strategic partnership that will harness Moderna's mRNA platform to accelerate the development of vaccines against viral disease outbreaks that threaten global health.

  • New expert advisory board appointments set to driv

    New expert advisory board appointments set to drive growth and innovation at Hongene

    • 27 Oct 2023
    • Editor

    Hongene, a leading biotech company in the nucleic acid manufacturing sector, has launched a new advisory board with international experts from academia and industry. This initiative is part of Hongene's commitment to advancing scientific research and accelerating its growth and innovation.

  • Moderna Named a Top Employer by Science for Ninth

    Moderna Named a Top Employer by Science for Ninth Consecutive Year

    • 27 Oct 2023
    • Editor

    Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.